Atezolizumab in understudied populations with bladder cancer
Sign Up to like & getrecommendations! Published in 2019 at "Nature Reviews Urology"
DOI: 10.1038/s41585-019-0200-8
Abstract: Immune checkpoint therapy is beneficial for patients with advanced bladder cancer; however, trials generally exclude patients with comorbidities or uncommon histologies. The SAUL trial demonstrates that atezolizumab is safe and efficacious in a patient population… read more here.
Keywords: bladder cancer; populations bladder; understudied populations; bladder ... See more keywords